Arcturus Therapeutics Ltd. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2015-06: Study NCT02477748; Company role Lead sponsor; Phase Phase 3; Status Terminated.
- 2014-08: Study NCT02189772; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2014-06: Study NCT02126995; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2014-03: Study NCT02059642; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2015-06 | NCT02477748 The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD | Lead sponsor | Phase 3 | Terminated | Attention Deficit Hyperactivity Disorder (ADHD) | 283 | 2017-01 |
| 2014-08 | NCT02189772 Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects | Lead sponsor | Phase 2 | Completed | ADHD, Predominantly Inattentive Type | 83 | 2015-01 |
| 2014-06 | NCT02126995 A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome | Lead sponsor | Phase 2 | Completed | Fragile X Syndrome | 62 | 2015-06 |
| 2014-03 | NCT02059642 A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) | Lead sponsor | Phase 2, Phase 3 | Completed Results posted | ADHD; Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type | 300 | 2014-09 |
| 2013-08 | NCT01933997 A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Healthy Adult Subjects | 16 | 2013-10 |
| 2013-08 | NCT01685281 Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder | Lead sponsor | Phase 2 | Completed | ADHD Predominantly Inattentive Type | 36 | 2013-12 |
| 2011-02 | NCT01243242 Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD) | Lead sponsor | Phase 2 | Completed Results posted | ADHD | 120 | 2011-09 |
| 2009-10 | NCT00995085 Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects | Lead sponsor | Phase 1 | Completed Results posted | Attention Deficit Hyperactivity Disorder | 43 | 2010-10 |